{"id":"anti-cgrp-mabs","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":["Injection site reactions","Constipation","Muscle spasms"],"contraindications":["Hypersensitivity to the antibody or excipients"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT06079801"],"aliases":[],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"anti-CGRP-mAbs","companyId":"cl-nica-de-intervenci-n-en-neurociencias","mechanism":{"target":"CGRP (Calcitonin Gene-Related Peptide) or CGRP receptor","novelty":"","modality":"Small molecule","drugClass":"","explanation":"CGRP is a neuropeptide released during migraine attacks that causes vasodilation and pain transmission. Anti-CGRP monoclonal antibodies either bind directly to CGRP ligand or to its receptor, preventing CGRP from activating pain pathways and reducing migraine frequency and severity.","oneSentence":"Monoclonal antibodies that bind to CGRP or its receptor, blocking the neuropeptide's role in migraine pain transmission and neurogenic inflammation.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123111,"model":"claude-sonnet-4-5-20250929"},"companyName":"Clínica de Intervención en Neurociencias","competitors":[{"name":"erenumab","brand":"Aimovig","company":"Amgen/Novartis","rationale":"First approved anti-CGRP receptor monoclonal antibody for migraine prevention"},{"name":"fremanezumab","brand":"Ajovy","company":"Teva","rationale":"Anti-CGRP ligand antibody for episodic and chronic migraine prevention"},{"name":"galcanezumab","brand":"Emgality","company":"Eli Lilly","rationale":"Anti-CGRP ligand antibody for migraine and cluster headache prevention"},{"name":"eptinezumab","brand":"Vyepti","company":"Lundbeck","rationale":"IV-administered anti-CGRP antibody for migraine prevention"}],"description":"Anti-CGRP monoclonal antibodies are a class of therapeutic agents that target calcitonin gene-related peptide (CGRP) or its receptor to prevent migraine headaches. These biologics block CGRP signaling, a key pathway involved in migraine pathophysiology, offering preventive treatment for patients with episodic or chronic migraine.","genericName":"anti-CGRP-mAbs","indications":{"approved":[{"status":"investigational","condition":"Migraine prevention","patientPopulation":"Adult patients with episodic or chronic migraine"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}